1
Decades of research on neuroendocrinological influences on animal behaviour has provided a 1 reliable basis for exploring it in humans [1] and motivate a growing scientific focus on the 2 biological basis of social aptitudes and the causes of their deficits [2] . One important element of 3 social cognition is "cognitive empathy", which constitutes the capacity to infer from observation 4 the emotions, beliefs, and goals of others. 1 This capacity exists across taxa [3] where its 5 impairment in humans characterizes a broad range of psychopathological conditions and is part 6 proposes that two distinct cognitive styles, "systemizing" and "empathizing", typify males and 10 females respectively. The stereotypically male systemizing domain has no social dimension, and 11 in its extreme form social cognition is extinguished. Guided by observations that ASDs emerge 12 early in life and are substantially more prevalent among males 3 , and that males typically score 13 lower than females in tests of cognitive empathy [6] , the EMB hypothesis proposes that elevated 14 prenatal exposure to the sex steroid testosterone causes impairments in cognitive empathy, 15 through its masculinizing effect on the developing brain [7] . 16
The EMB hypothesis found evidential support in a study that reported a correlation between 17 amniotic testosterone levels and ASD traits ([8] , though see [9] ), and has remained popular yet 18 controversial to date. Much of its research has relied on the assumption that the ratio between the 19 hand's second (index) to fourth (ring) digit (known as 2D:4D) is a developmental proxy for 20 1 Cognitive empathy is the ability to interpret others' emotions and understand their behaviour vis-a-vis their emotional state; this is distinct from emotional empathy, which is the vicarious feeling of others' emotions along with them (Smith 2006). 2 The DSM V criteria for ASDs include "Non-verbal communication problems, such as abnormal eye contact, posture, facial expressions, tone of voice and gestures, as well as an inability to understand these." 3 ASD incidence rates vary widely by study, from 5.2 to 72.6 per 10,000 people and ratios range from 1.81 to 15.7 male:female. prenatal testosterone exposure [10] , which motivated examinations of correlations between 1 2D:4D and cognitive empathy and ASDs occurrences. While some studies provided supporting 2 evidence (e.g., [11] ), several others failed to detect a relationship between digit ratio and 3 cognitive empathy [12, 13] . Moreover, because it is not feasible to experimentally manipulate 4 prenatal testosterone exposure in humans (due to ethical considerations), findings along this line 5 of research have been correlational, which cannot establish causal relations [8] . 6
Testing testosterone's causal effect on cognitive empathy 7
A handful of experiments attempted to address the above limitation by testing the effects of 8 testosterone administration on cognitive empathy in neurotypical adults, and investigating the 9 dependency of these effects on the 2D:4D biomarker [14] [15] [16] [17] . This line of research critically 10 relies on an assumption originating in animal research, that in utero androgen exposure 11 moderates the activational effect of testosterone [18] . The seminal publication along this line of 12 research reported a placebo-controlled within-subject experiment of 16 healthy females, in which 13 exogenously administered testosterone strongly impaired cognitive empathy measured using the 14 "Reading the Mind in the Eyes Test" (RMET), a 36-item battery testing the ability to infer 15 others' emotional states and intentions from pictures of their eye regions [6] (see Fig. S2 in 16
Supplementary Material for example item). In addition to reporting a main effect of exogenous 17 testosterone reducing cognitive empathy, more than 50% of the individual differences in the 18 effect on the RMET were explained by the participants' variation in the right-hand 2D:4D, 19 implying involvement of prenatal testosterone exposure in the causal effect [17] . 20
A similar experiment with roughly twice the sample size (N=33, all female sample) found a 1 much smaller 4 main effect (P=0.048, one-tailed), and no moderation by 2D:4D [16] . A third 2 experiment of 16 females found neither a main effect nor a moderation by 2D:4D [15]. Last, one 3 experiment investigated the effect of testosterone administration on the RMET in 30 healthy 4 males and found neither a main effect nor a moderation by the right-hand 2D:4D; however, 5 subsample analysis revealed that testosterone administration reduced cognitive empathy in 6 participants with relatively low (i.e., more masculine) left-hand 2D:4D, but no relationship for 7 high 2D:4D or either for the right hand [14] . 8
Do the data support the hypothesis? 9
Despite these earlier findings the current literature on the effects of testosterone on cognitive 10 empathy is subjected to important limitations and results reveal weaknesses under scrutiny. First, 11 albeit there are a few parallel findings in terms of negative direction of effect of testosterone on 12 RMET performance, there is a lack of replicability across experiments, where only one of the 13 four studies observed a statistically significant (P<0.05) main effect of testosterone on the RMET 14
[17]. Moreover, this publication's report of a strong moderating role of the right-hand 2D:4D 15 was not replicated in any of the other studies (the only other report of an interaction between 16 testosterone administration and the 2D:4D was observed for the left hand [14]). 5 17 A second concern is statistical power. Although the RMET is a noisy psychological instrument, 6 18 and 2D:4D is, at best, a noisy proxy of prenatal testosterone exposure [19] , all samples ranged 19 between 16 and 33 participants, which might have been too meager to credibly estimate a true 20 effect size. It is therefore impossible to know whether the inconsistencies in the literature are due 1 to an absence of a true association, or the result of false negative findings due to low statistical 2 power. Thus, these inconsistent results necessitate clarification through additional studies. 3
To this end, we conducted a powerful direct test of the activational and developmental effects of 4 testosterone on cognitive empathy by measuring the causal effect of exogenous testosterone and 5 the moderating role of putative prenatal androgenic biomarkers in two studies of healthy young 6 men. Our studies constitute the two largest behavioural testosterone administration experiments 7 conducted to date, with samples that were 15 and 25 times greater than the first study that 8 reported a statistically significant effect of testosterone on the RMET in females [17] and 7 and 9 12 times greater than the largest experiment in males [14] . In both studies we used a computer-10 based version of the RMET to test the hypothesis that testosterone administration and its 11 purported developmental biomarkers affect cognitive empathy. 12
Methods 13

Experiment 1 14
Participants and experimental procedure. Two hundred forty-three males aged 18 to 55 (mean 15 age=23.63, SD=7.22) participated in the study and were mostly private Southern California 16 consortium students from diverse ethnic backgrounds (see Participants section and Table S1a in 17
Supplementary Material). The institutional review boards of Caltech and Claremont Graduate 18
University approved the study, all participants gave informed consent, no adverse events 19 occurred during any experimental session, and no participant or researcher was harmed. All data 20 and materials are available on the Open Science Framework (https://osf.io/hztfe/). 21
Participants registered by their preferred session dates and were added to cohorts of 13 to 16. 1
They arrived at the lab at 9 a.m., signed informed consent forms, and had both of their hands 2 scanned before being randomly assigned to private cubicles where they completed demographic 3 and mood questionnaires (see Supplementary Material for all independent variables) and 4
provided an initial saliva sample by passive drool. Next, participants proceeded to gel application 5 (further details below), after which they were given printed material containing precautions and 6 instructions prior to dismissal (experimental timeline shown in Fig. 1 ). All participants returned 7 to the lab at 2 p.m., provided a second saliva sample, and began a battery of tasks that lasted 8 approximately two hours. We did not randomize the order of the behavioral tasks, in similar 9
fashion to previous studies [20], to standardize hormonal measurements (which have diurnal 10 cycles) among participants. Following the experiment, participants completed an exit survey, 11
where they indicated their beliefs about the treatment they had received using a five-point scale. 12 Treatment administration. Following initial intake, participants were escorted in groups of two 13 to six to a semiprivate room. There they were provided en masse small plastic cups containing 14 either 10 g of topical testosterone that is a widely prescribed transdermal testosterone gel with 15 clearly mapped pharmacokinetics [21] (100 mg, Vogelxo TM , N=123) or volume equivalent of 16 inert placebo of similar viscosity and texture placebo (80% alcogel, 20% Versagel ® , N=118) 17 under a double-blind protocol (see Fig. S1a in Supplementary Material for randomization 18 protocol). Participants were instructed to apply the entirety of the gel container following 19 manufacturer instructions. to treatment administration, shortly after returning for afternoon session, another closely 22 following the RMET, and a final sample prior to exit survey) for subsequent assay (see 23
Supplemental Material for precise timing). To allow robust manipulation checks and obtain 1 statistical control for hormonal markers of participants' biological states, we used liquid 2 chromatography tandem mass spectrometry (LC-MS/MS, detection levels and precision are 3 available in Supplementary Material Table S2 ) to measure the following salivary steroids: 4 estrone, estradiol, estriol, testosterone, androstenedione, DHEA, 5-alpha DHT, progesterone, 5 17OH-progesterone, 11-deoxycortisol, cortisol, cortisone, and corticosterone (see Supplemental  6 Material Table S7 for measurements). 7 Digit Ratio Measurements. Participants' hand scans acquired at intake were measured by two 8 independent raters using and digital calipers to quantify 2D:4D; inter-rater correlation was 0.96 9
and their scores were averaged. 10 Behavioural task. We administered the adult version of the RMET developed by Baron-Cohen 11 and colleagues [6] which shows the eye region of an actor's face, and a list of four words that 12 describe emotional states and cognitive processes among which participants select the one that 13 best described the person in the image (see Fig. S2 in the Supplemental Material for example 14 item). The task was divided into two segments, baseline (morning) and post-treatment 15 (afternoon), in a repeated measures design (see Fig. 1 
below): each participant completed a half 16
of the RMET in the morning (either part "A", items 1-18, or part "B", items 19-36) prior to 17 receiving treatment, and the other half following treatment when, according to published 18 pharmacokinetics, androgen levels are elevated and stable following exogenous application. 19 Psychological Questionnaires. Because there are various feasible channels through which 20 testosterone could affect RMET performance (and affect being one of them), we measured mood 21
using the PANAS-X scale [22], both pre-and post-treatment (see Table S1a in Supplementary  22 Material for aggregated responses). 1
Experiment 2 2
Participants. Experiment 2 included both students and participants from the general public for a 3 total sample of 400 participants (mean age=22.80, SD=4.68). The all-male sample was 4 composed predominantly of Caucasians and overall ethnic heterogeneity was representative of 5 the region (see Participants section and Table S1b in Supplementary Material). All accepted 6 participants completed the task and were included in the analysis (for pre-screening criteria see 7
Supplementary Material). The Nipissing University Research Ethics Board approved this study, 8 all participants gave informed consent, no adverse events occurred during any experimental 9 session, and no participant or researcher was harmed. completed an exit survey asking which treatment they believed they had received (see Figure  19 S1b in Supplementary Material). 20
Treatment administration. Following initial saliva sample collection, a researcher provided 21 two syringes pre-filled by a pharmacist following a double-blind protocol each containing 5.5 mg 22 of either placebo or testosterone gel (for a total of 11 mg). This is a newly approved nasal gel 1 used for the treatment of hypogonadism. Pharmacokinetic data indicate that serum testosterone 2 concentrations rise sharply within 15 minutes of testosterone gel application and remain elevated 3 (relative to placebo) up to 180 minutes post-application [23]. The gel was either Natesto® or the 4 volume equivalent of an inert placebo of similar viscosity and texture. Random assignment was 5 determined such that half the participants in every group received testosterone and half received 6 placebo such that total participants base was bisected with N=200 for both testosterone and 7 placebo groups (see Fig. S1b in Supplementary Material for randomization protocol). 8 Saliva samples. Each participant provided two saliva samples, with the first sample collection 9 time 30 minutes following arrival (and prior to gel application), and the second 120 minutes after 10 arrival. Participants provided passive drool into a 5 ml polystyrene tube while situated in their 11 individual testing rooms as instructed by a research assistant and samples were analyzed for pre-12 and post-treatment testosterone and baseline cortisol using commercially available enzyme 13 immunoassay kits (DRG International) (see Table S2b in Supplementary Material for hormone 14 measures). 15 Digit Ratio Measurements. Participants' 2D:4D were measured by two independent raters 16 using hand scans and digital calipers with an inter-rater correlation of 0.86 and their scores were 17 averaged. We note several differences between our study and the primary positive report of testosterone 6 administration on the RMET in 16 females [17] . to note that the pharmacokinetic data for sublingual administration (published in Fig. 1 of Tuiten 20 et al. [24] ) show that at the time the task was performed-4 hours after sublingual 21 administration-participants' testosterone levels were the same across the testosterone and 1 placebo groups. Moreover, the Tuiten et al. study that served as a justification for using a 4-hour 2 delay had only 8 participants, and reported a statistically weak treatment effect (p=0.04, 3 uncorrected for multiple comparisons). 4
In Experiment 1 we chose to administer testosterone using an FDA-approved transdermal gel for 5 three reasons. First, transdermal gel had been extensively studied in the medical literature both 6 prior and following its approval [25, 26] . Second, one of our laboratories found reliable 7 behavioural effects with robust manipulation check in serum using a single dose [27] , and third, 8 the pharmacokinetics of a single-dose of this testosterone administration method were mapped 9
prior to the inception of our experiments by a study showing that plasma testosterone levels 10 peaked 3 hours after single-dose exogenous transdermal administration, and stabilized at high 11 levels between 4 and 7 hours following administration [21] . 7 Therefore, we had all participants 12 return to the lab 4.5 hours after receiving gel, when androgen levels were elevated and stable. 13
We used a 100 mg transdermal dose, which quickly elevates then holds testosterone levels high 14 and stable for approximately 24 hours [25] and was shown to generate effects on cognition, 15 decision making, and other behaviours [27, [29] [30] [31] . 16
In Experiment 2 we used nasal delivery, following a recent study indicating that serum 17 testosterone concentrations rise sharply within 15 minutes after Natesto® gel application and 18 remain elevated for approximately three hours post application among hypogonadal males [23] 19 (see Fig. S3 in Supplementary Material). This method conforms to our experimental paradigm's 20 pharmacokinetic structure as serum testosterone approached its zenith in treated participants as 21 they completed the RMET (see Supplementary Material Tables S2a and b for testosterone  22 7 Subsequent studies measuring testosterone in serum in significantly larger sample sizes demonstrate an earlier hormonal peak at 60 minutes post administration with subsequent stabilization [14,25].
levels). 1
The doses in both experiments are commonly prescribed daily to men with low circulating 2 testosterone levels and serve as two distinct physical transport channels (transdermal and 3 intranasal, respectively) to reduce the probability that behavioural effects are transport channel 4 specific. Various studies show significant heterogeneity in change in testosterone levels 5 depending on delivery method, location of application in the body, and biofluid measured 6
[14,21,24,27,29,32]. However, all the exogenous delivery methods in this particular literature 7 cause a common hormonal trajectory characterized by a rapid initial rise, a peak above typical 8 circulating levels, and eventual return to baseline. 
Manipulation check 20
In both experiments, pre-treatment (i.e., baseline) saliva testosterone levels were similar across 21 the two treatment groups, and post-treatment saliva testosterone levels were greater in the 1 testosterone group compared with the placebo group. In experiment 1, the mean logged pre-2 treatment testosterone level was 5.58 pg/ml (SD=0.08) in the testosterone group and 5.77 pg/ml 3 (SD=0.09) in the placebo group (two-sided t-test: P=0.13, t(239)=1.50). Mean post-treatment 4 logged testosterone levels were 8.38 pg/ml (SD=0.15) in the testosterone group and 5.11 pg/ml 5 (SD=0.08) in the placebo group, 8 (t(239)=18.43, P<0.0001). Likewise in experiment 2, we find 6 similar mean baseline saliva testosterone concentrations between the groups, with l5.3 pg/ml 7 (SD=0.88) in the testosterone group and 5.4 pg/ml (SD=0.85) in the placebo group (two-sided t-8 test: P=0.49, t(394)=0.69). The mean logged post-treatment saliva testosterone levels were (8.00 9 pg/ml, SD=1.27) in the testosterone group and 5.33 pg/ml (SD=0.73) in the placebo group (two-10 sided t-test: P<0.001, t(396)=22.14) (see Fig. 1 
and Tables S2a and S2b in Supplementary 11
Material). 12
Consistent with previous reports, we found no treatment effects on mood and treatment 13 expectancy (e.g., [34]) (see Table S2a and S2b in Supplement), or levels of other hormones 14 unaffected by exogenous testosterone, as measured by LC-MS/MS in Experiment 1 or enzyme 15 immunoassay in Experiment 2 (see Tables S1a and S1b in Supplement). 16
Influence of Testosterone on RMET scores 17
Overall RMET scores in our samples were comparable with previous studies of similar 18 populations (see Fig. 2A below) . Figure 2B shows baseline and post-treatment RMET scores in 19 Experiment 1, separated by treatment group and order. As expected, baseline (morning) RMET 20 performance were reliably correlated with afternoon scores (r(241)=0.40, P<0.001). In addition, 21 participants' scores were, on average, slightly higher in the B portion of the test (A portion 1 average=13.54, SD=2.43; B portion average=13.95, SD=2.19, t(241)=2.53, P=0.01). Figure 2C  2 shows Experiment 2 scores by treatment groups. 3 d=0.19. A sample of at least 870 participants (in a between-subject design), or 435 subjects (in a 20 9 These include RMET baseline scores, portion A or B, 2D:4D and treatment interactions, Cognitive Reflection Task (CRT) scores, math abilities, mood and affective measures, treatment expectancy, age, marital status, sexual preference, and all other measured hormones that were not influenced by testosterone treatment and may affect cognition and decision-making (e.g., cortisol [35, 36] ). The CRT control was added because performance is impaired by exogenous testosterone [29] and people with ASD outperform non-ASD age-matched controls [37]. 10 These include Cognitive Reflection Task (CRT) scores, factor 1 and 2 psychopathy measures, treatment expectancy, age, marital status, sexual preference, and all other measured hormones that were not influenced by testosterone treatment.
within-subject design), which is over 26 to 54 (within-subject 13 to 26) times greater than 1 previous investigations, would be required to reliably detect even this "optimistic" negative 2 effect size estimate with statistical power of 0.8. Regression analyses with comprehensive 3 controls corroborate the absence of a main treatment effect, and the absence of moderation by 4 2D:4D (right hand, left hand, and their average), as implied by insignificant interaction 5 coefficients (see Supplementary Material, Table S3a ). Furthermore, in an analysis analogous to 6 the previous positive report [17], we found no correlation between the treatment effect on the 7 CI did not include negative effects of testosterone administration on the RMET that were greater 14 in magnitude than 0.15. Further analyses of each question in isolation using Chi-squared tests 15 revealed no systematic differences between treatment conditions in any of the RMET items in 16 both experimental datasets (see Supplementary Material Tables S5a and b) . 17
Testing for effect of 2D:4D 18
Putative prenatal testosterone proxies (2D:4D, either right-hand, left-hand, or their average) did 19 not correlate with RMET scores in both experiments or moderate the effect of testosterone 20 administration, echoing other recent findings [14-16] (see Supplementary Material Tables S3a-21 S4b). These results are in line with previous reports showing no correlation between the 2D:4D 22 and RMET scores [12, 38, 39] , and in contrast to the two papers reporting an interaction between 1 2D:4D and the exogenous testosterone's effect on the RMET [14,17]. 2
Discussion 3
Our experiments used two notably large samples to test the effects of pharmacological 4 testosterone manipulation on cognitive empathy. Despite experimental differences between 5 them, their collected data exhibit the same results with robust statistical consistency, to 6 demonstrate a lack of effects of testosterone administration and 2D:4D on cognitive empathy. 7
These findings, and the literature as a whole, cast serious doubts on the proposal that testosterone 8 causally impairs cognitive empathy, for several reasons. 9
First, the low statistical power of previous investigations undermines their reliability in capturing 10 true effects. Even if we assume that a purported size of testosterone's negative effect on 11 cognitive empathy is the overly "optimistic" negative bound of our confidence interval for d=-12 0.19 in Experiment 1, we find that all previous investigations of the topic were statistically 13 underpowered (<0.3 power). Second, the results of the previous small sample studies are 14 discrepant. Our large samples draw on drastically more data than all previous investigations 15 combined, and generalize across geographically, economically, and culturally distinct 16 populations (see Participants section of Supplementary Material). Our use of two different 17 experimental designs and testosterone administration protocols across these populations further 18 mitigates the concern that the outcomes were due to a particular experimental factor. Of note, 19 there are some design differences between our studies and previous investigations (see Table 1 ; 20 differences from [17] discussed above). However, even if those design differences led to a 21 complete abolishment of a "real" effect of testosterone on cognitive empathy, our results 22 demonstrate beyond a reasonable doubt that such an effect is not generalizable to both males and 23 females. Future work with females could employ a similar approach as ours characterized by 1 large samples from different geographies, distinct administration methods, and other design 2 features that strongly inform whether a relationship (or its absence) generalizes across sexes. 3 1 patients were found to be only somewhat feminized, and had the same variance as in healthy 2 controls, demonstrating that the preponderance of individual differences in the measure is not 3 attributable to the influence of testosterone exposure [19] . There is also longitudinal evidence 4 that 2D:4D systematically changes during childhood [43, 44] , which is unconformable with the 5 preposition that it accurately quantifies prenatal influences. Moreover, while many studies report 6 2D:4D sexual dimorphism [45, 46] , other studies suggest lack of ethnic universality of 7 dimorphism [47, 48] . Finally, there is also a debate on whether sexual dimorphism is the product 8 of allometric shift in shape rather than hormonal influences [49, 50] . 9
Furthermore, many reports of correlations between 2D:4D and behavioural traits hold only for 10 subsets of the population (e.g., particular sex or race). Correlation sometimes holds only for the 11 right hand 2D:4D but in other times only for the left hand, or for the average of both hands [51] . 12
Overall, significant results are seldom replicated, and few survive correction for multiple 13 comparisons or meta-analytic aggregations (e.g., [52] ). These concerns belie the validity of the 14 measure as a biomarker and its capacity to detect reliable correlations with noisy psychological 15 constructs in studies of small samples. 16
Despite our dissenting results, the absence of evidence is not necessarily evidence of absence. 17
Specifically, the lack of an association between 2D:4D and cognitive empathy could be 18 attributable to the failure of the measure to serve as a reliable androgenic biomarker. We 19 therefore agree with Baron-Cohen et al.
[53] (p. 6) that it is worthwhile to study the occurrence 20 of impaired cognitive empathy and other ASD traits in developmentally unique populations. One 21 such study reported mixed evidence of higher scores in some Autism Quotient self-rating 22 subscales among women with congenital adrenal hyperlexia (CAH) and lower scores in other 23 subscales, compared with their unaffected relatives [54], with no significant results in men. 1
However, results along this line of research, too, are far from being conclusive. For example, [9] 2 found that young females with and without CAH did not differ in autistic traits, and that amniotic 3 testosterone levels were not associated with scores from either sex individually or the entire 4 sample. Other longitudinal studies also found no association between various measures of 5 prenatal androgens measured in umbilical cord blood and amniotic fluid and autistic traits 6 Time-coded experimental timeline shows that, following intake (morning), participants completed half of the RMET (portion A or B), provided a saliva sample, and received gel prior to being dismissed. Upon their return to the lab (afternoon), another saliva sample was collected prior to taking the second portion of the RMET (B or A) (Standard errors shown).
Timeline generalizes experimental sequence for all three start times for Experiment 2. Following arrival and completion of consent and self-report questionnaires, participants provided a saliva sample approximately 30 minutes prior to drug administration. The second sample was collected at the end of a two-hour protocol approximately one-and-a-half hours after drug administration and fifteen minutes after the RMET. 12 13
